share_log

Enanta Pharma Analyst Ratings

エナンタファーマのアナリスト評価

Benzinga ·  2023/11/22 13:46
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/22/2023 127.52% Oppenheimer $25 → $21 Maintains Perform
11/21/2023 203.36% HC Wainwright & Co. $30 → $28 Maintains Buy
11/21/2023 149.19% JMP Securities $42 → $23 Maintains Outperform
10/23/2023 225.03% HC Wainwright & Co. $48 → $30 Maintains Buy
10/02/2023 62.51% RBC Capital $25 → $15 Maintains Sector Perform
09/19/2023 420.04% HC Wainwright & Co. → $48 Reiterates Buy → Buy
08/09/2023 170.86% Oppenheimer $30 → $25 Maintains Perform
08/08/2023 420.04% HC Wainwright & Co. → $48 Reiterates Buy → Buy
08/08/2023 170.86% RBC Capital → $25 Reiterates Sector Perform → Sector Perform
08/08/2023 355.04% JMP Securities $65 → $42 Maintains Market Outperform
08/08/2023 95.02% Jefferies $49 → $18 Downgrades Buy → Hold
05/11/2023 225.03% Oppenheimer $50 → $30 Reiterates Perform → Perform
05/09/2023 257.53% RBC Capital $48 → $33 Maintains Sector Perform
05/09/2023 420.04% HC Wainwright & Co. $68 → $48 Maintains Buy
05/09/2023 604.23% JMP Securities $82 → $65 Maintains Outperform
03/22/2023 485.05% RBC Capital → $54 Reiterates → Sector Perform
02/09/2023 430.88% SVB Leerink → $49 Reiterates → Market Perform
02/08/2023 842.58% Piper Sandler → $87 Maintains Overweight
02/08/2023 550.05% JP Morgan $74 → $60 Maintains Neutral
01/27/2023 430.88% SVB Leerink $50 → $49 Maintains Market Perform
12/09/2022 506.72% HC Wainwright & Co. → $56 Initiates Coverage On → Buy
11/22/2022 485.05% RBC Capital $65 → $54 Maintains Sector Perform
08/10/2022 539.22% Oppenheimer $53 → $59 Maintains Perform
08/09/2022 1384.29% JMP Securities $103 → $137 Maintains Market Outperform
08/09/2022 615.06% RBC Capital $67 → $66 Maintains Sector Perform
08/01/2022 474.21% Oppenheimer $45 → $53 Maintains Perform
08/01/2022 441.71% SVB Leerink $44 → $50 Maintains Market Perform
07/06/2022 571.72% Evercore ISI Group → $62 Upgrades In-Line → Outperform
07/01/2022 625.89% RBC Capital $64 → $67 Maintains Sector Perform
06/01/2022 322.54% Evercore ISI Group → $39 Upgrades Underperform → In-Line
05/20/2022 387.54% Oppenheimer $70 → $45 Maintains Outperform
05/19/2022 875.08% Baird $130 → $90 Maintains Outperform
05/19/2022 1015.93% JMP Securities $114 → $103 Maintains Market Outperform
05/19/2022 376.71% SVB Leerink $58 → $44 Maintains Market Perform
05/12/2022 658.4% Roth Capital $101 → $70 Maintains Buy
05/10/2022 1135.1% JMP Securities $116 → $114 Maintains Market Outperform
05/10/2022 528.39% SVB Leerink $68 → $58 Maintains Market Perform
05/10/2022 593.39% RBC Capital $72 → $64 Maintains Sector Perform
02/09/2022 636.73% SVB Leerink $80 → $68 Maintains Market Perform
01/13/2022 766.74% SVB Leerink $85 → $80 Maintains Market Perform
11/24/2021 690.9% Oppenheimer $55 → $73 Maintains Perform
11/23/2021 1156.77% JMP Securities $111 → $116 Maintains Market Outperform
11/23/2021 820.91% SVB Leerink $92 → $85 Maintains Market Perform
11/19/2021 680.07% RBC Capital $74 → $72 Maintains Sector Perform
11/19/2021 1102.6% JMP Securities $121 → $111 Maintains Market Outperform
11/08/2021 1210.94% JMP Securities $77 → $121 Maintains Market Outperform
11/08/2021 896.75% SVB Leerink $55 → $92 Maintains Market Perform
10/20/2021 701.73% RBC Capital $58 → $74 Maintains Sector Perform
10/20/2021 734.24% JMP Securities $73 → $77 Maintains Market Outperform
10/07/2021 929.25% Jefferies → $95 Initiates Coverage On → Buy
09/09/2021 495.88% SVB Leerink → $55 Initiates Coverage On → Market Perform
08/09/2021 441.71% RBC Capital $52 → $50 Maintains Sector Perform
08/06/2021 441.71% RBC Capital $52 → $50 Maintains Sector Perform
08/06/2021 734.24% JMP Securities $70 → $77 Maintains Market Outperform
01/29/2021 495.88% JP Morgan $44 → $55 Upgrades Underweight → Neutral
11/24/2020 225.03% Evercore ISI Group → $30 Initiates Coverage On → Underperform
08/28/2020 1026.76% Roth Capital → $104 Reinstates → Buy
08/26/2020 842.58% Piper Sandler → $87 Initiates Coverage On → Overweight
07/27/2020 658.4% JMP Securities → $70 Upgrades Market Perform → Market Outperform
03/17/2020 550.05% Baird → $60 Upgrades Neutral → Outperform
11/22/2019 JMP Securities Downgrades Market Outperform → Market Perform
09/26/2019 517.55% JP Morgan $86 → $57 Downgrades Neutral → Underweight
12/13/2018 766.74% Berenberg → $80 Initiates Coverage On → Buy

What is the target price for Enanta Pharma (ENTA)?

The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by Oppenheimer on November 22, 2023. The analyst firm set a price target for $21.00 expecting ENTA to rise to within 12 months (a possible 127.52% upside). 21 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Enanta Pharma (ENTA)?

The latest analyst rating for Enanta Pharma (NASDAQ: ENTA) was provided by Oppenheimer, and Enanta Pharma maintained their perform rating.

When is the next analyst rating going to be posted or updated for Enanta Pharma (ENTA)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enanta Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enanta Pharma was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.

Is the Analyst Rating Enanta Pharma (ENTA) correct?

While ratings are subjective and will change, the latest Enanta Pharma (ENTA) rating was a maintained with a price target of $25.00 to $21.00. The current price Enanta Pharma (ENTA) is trading at is $9.23, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする